1.39

7.33% -0.11

After Hours: 1.38 -0.01 -0.72%

Longeveron Inc (LGVN)

Overview News Price History Financials Discussions Forecast Stock Split

Longeveron Inc stock is traded at $1.39, with a volume of 66,037. It is down -7.33% in the last 24 hours and down -79.19% over the past month. Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Previous Close:

$1.50

Open:

$1.47

24h Volume:

66,037

Relative Volume:

0.83

Market Cap:

$4.43M

Revenue:

$1.22M

Net Income/Loss:

$-22.43M

P/E Ratio:

-1.202

EPS:

-1.1564

Net Cash Flow:

$-18.78M

1W Performance:

-43.95%

1M Performance:

-79.19%

6M Performance:

-87.36%

1Y Performance:

-83.20%

1-Day Range:

$1.36

$1.4906

1-Week Range:

$1.36

$2.55

52-Week Range:

$1.36

$12.30

Longeveron Inc Stock (LGVN) Company Profile

Name

Longeveron Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

305-302-7158

Address

1951 NW 7TH AVENUE, MIAMI

Employee

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

LGVN's Discussions on Twitter

Compare LGVN vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGVN Longeveron Inc	1.39	4.43M	1.22M	-22.43M	-18.78M	-1.1564
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-24	Initiated	ROTH MKM	Buy

Longeveron Inc Stock (LGVN) Latest News

Oct 09, 2026

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes - Investing News Network

Oct 09, 2026

Oct 07, 2026

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - Investing News Network

Oct 07, 2026

Oct 05, 2026

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - Investing News Network

Oct 05, 2026

Longeveron CEO Stephen H. Willard Discloses RSU Tax Withholding Share Disposal - Kalkine Media

Oct 05, 2026

Oct 01, 2026